Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1300 participants.

Also called NCT04258488

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,300 participants (planned count) (from the registry)
Sponsor
Joon Bum Kim (from the registry)
Registry
  • NCT NCT04258488
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04258488. Randomized; no masking; primary purpose treatment. Start 2022-02-21 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement
Acronym
RENOVATE
Condition
AORTIC VALVE DISEASES
Condition
Thromboembolism
Intervention (Drug)
Rivaroxaban Oral Tablet
Intervention (Drug)
Vitamin K antagonist(warfarin)
Lead sponsor
Joon Bum Kim (class: other)

Record details

Record id
cardio:ct-nct04258488
Content hash
12fcfd7ba847121e5aea0a76ae95af90d516e75ab743588a2f918f604dd01b85